#Saudi Arabia #Riyadh #Bio-Thera #BAT2206 #Tabuk Pharmaceuticals

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals for BAT2206

In a significant move for the healthcare landscape in Saudi Arabia, Bio-Thera Solutions Inc. has announced a partnership with Tabuk Pharmaceutical Manufacturing Company to commercialize BAT2206, a biosimilar version of Stelara® (ustekinumab). This collaboration aims to bolster the availability of advanced therapeutic options in the region, especially for patients with autoimmune diseases.

Bio-Thera, a renowned biopharmaceutical company based in Guangzhou, China, specializes in developing innovative therapies and biosimilars. The partnership grants Tabuk exclusive rights to manufacture, distribute, and market BAT2206 in Saudi Arabia. This strategic collaboration leverages Tabuk’s well-established presence and marketing acumen in the MENA region, promising to improve patient access to essential medications.

Dr. Shengfeng Li, CEO of Bio-Thera, expressed his enthusiasm for the deal, stating, "We are pleased to establish a partnership with Tabuk to commercialize our ustekinumab biosimilar program in Saudi Arabia. Tabuk is a leading pharmaceutical company in the MENA region and is a great partner to ensure patients in Saudi Arabia have the best access to BAT2206." This reflects Bio-Thera's commitment to address the local healthcare needs by providing high-quality therapeutics.

Under the partnership, Tabuk Pharmaceuticals will assume the role of holding marketing authorization and will be responsible for the registration, importation, and promotion of BAT2206. In contrast, Bio-Thera will manage the complete development and commercial supply from its facilities in China. This division of responsibilities is expected to streamline operations, enhance efficiency, and ensure compliance with regulatory standards.

BAT2206 represents a promising biosimilar alternative to Jhansen's Stelara®, which has demonstrated efficacy in treating various inflammatory conditions. Specifically, Stelara® is known for providing relief for chronic diseases such as Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and psoriatic arthritis.

Stelara® functions by inhibiting the biological activity of interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines that play vital roles in the immune and inflammatory processes. By blocking the shared p40 subunit from binding to the IL-12Rβ1 receptor on immune cells, BAT2206 aims to mitigate the inflammatory responses associated with these chronic diseases.

The launch of BAT2206 in Saudi Arabia aligns seamlessly with Tabuk Pharmaceuticals’ vision. Ismail Shehada, CEO of Tabuk, commented, "We are excited to announce our partnership with Bio-Thera that will enable us to deliver unique and specialized health solutions aimed at enhancing the well-being of people in Saudi Arabia. We are confident that this partnership supports our efforts to manufacture and localize biosimilar products in the region, thereby strengthening our market-leading position in alignment with our strategy."

This collaboration stands as a testament to both companies’ dedication to enhancing healthcare access and supporting the well-being of patients in the region. Furthermore, it underscores a shared commitment towards fulfilling the goals laid out in Saudi Arabia's Vision 2030, which emphasizes local production of therapeutics and the advancement of the kingdom’s pharmaceutical industry.

With this partnership, Bio-Thera and Tabuk Pharmaceuticals are poised to play a pivotal role in transforming the pharmaceutical landscape in Saudi Arabia. Through innovative solutions and localized production, they aim to ensure that patients receive timely, effective, and affordable healthcare solutions.

As BAT2206’s regulatory approvals progress in various markets including China, Europe, and the US, the anticipation builds for its launch in Saudi Arabia, signaling a new chapter in accessible healthcare in the MENA region. The partnership is set to resonate positively among healthcare providers and patients alike, paving the way for improved therapeutic options for those suffering from chronic autoimmune conditions.

For more information about Bio-Thera Solutions and the significance of this partnership, visit their official website.